Sean Harper

Nature Reviews Drug Discovery 17, 10 (2018). doi:10.1038/nrd.2017.262 Amgen bought deCODE genetics for US$415 million in December 2012, with a plan to ramp up their use of human genetic data in drug discovery and development. This deal has since transformed Amgen's pipeline, says Amgen Chief Scientific Officer Sean Harper. A treasure trove of genetic data from more than 160,000 Icelanders now informs everything from target selection to clinical trial design. Genetic insights, sequencing capabilities and analytical expertise have helped the company to avoid costly failures, prosecute programmes more effectively and discover de novo drug targets, he told Asher Mullard.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research